Swiss Biotech · Allschwil, Switzerland
Tumor-activated nanobody therapeutics for hard-to-treat solid tumors
We develop conditionally active nanobody-drug conjugates (CA-NDCs) that remain silent in healthy tissue and switch on in the acidic tumor microenvironment, solving the fundamental limitations of antibody-drug conjugates (ADCs).
About
A new class of cancer medicines
Nanolynx Biologics AG is a Swiss biotech spinout of Ability Biotherapeutics, founded to develop conditionally active nanobody-drug conjugates (CA-NDCs) for hard-to-treat solid tumors.
Conventional antibody-drug conjugates (ADCs) — the current best-in-class approach — fail because they cannot penetrate solid tumors effectively and they cause severe toxicity in healthy tissue. We solve both problems simultaneously. Our CA-NDCs are 10× smaller than antibodies for deep tumor diffusion and are engineered to activate only in the acidic tumor microenvironment, sparing healthy tissue.
Validated Biology
ADCs and nanobodies are clinically and commercially proven. Our targets (CD70, CD142) are validated by approved drugs, yet constrained by ADC toxicity which is precisely the gap CA-NDCs fill.
Proprietary Data & Know-How
Exclusive license to one of the world’s largest nanobody datasets: 200 million datapoints across 15 oncology targets, purpose-built for machine learning and unavailable to competitors.
Next-Gen Modality
Conditionally active nanobody-drug conjugates — CA-NDCs — represent a fundamentally new therapeutic class combining the penetration advantages of nanobodies with tumor-selective payload release.
About
A new class of cancer medicines
Nanolynx Biologics AG is a Swiss biotech spinout of Ability Biotherapeutics, founded to develop conditionally active nanobody-drug conjugates (CA-NDCs) for hard-to-treat solid tumors.
Conventional antibody-drug conjugates (ADCs) — the current best-in-class approach — fail because they cannot penetrate solid tumors effectively and they cause severe toxicity in healthy tissue. We solve both problems simultaneously. Our CA-NDCs are 10× smaller than antibodies for deep tumor diffusion and are engineered to activate only in the acidic tumor microenvironment, sparing healthy tissue.
Next-Gen Modality
Conditionally active nanobody-drug conjugates — CA-NDCs — represent a fundamentally new therapeutic class combining the penetration advantages of nanobodies with tumor-selective payload release.
Proprietary Data & Know-How
Exclusive license to one of the world’s largest nanobody datasets: 200 million datapoints across 15 oncology targets, purpose-built for machine learning and unavailable to competitors.
Validated Biology
ADCs and nanobodies are clinically and commercially proven. Our targets are validated by approved drugs, yet constrained by ADC toxicity which is precisely the gap CA-NDCs fill.
Technology
IntelliBody™ Platform
IntelliBody™ uses generative AI trained on our proprietary nanobody dataset to engineer pH-dependent binding, making our drugs inactive at physiological pH 7.4, but fully active in the acidic tumor microenvironment.
Proprietary
Exclusive license to the Distributed Bio VHH library through Ability Biotherapeutics — among the world’s largest nanobody-antigen interaction datasets ever assembled.
AI-Enabled
Protein language models screen billions of conditionally active variants, compressing what would take years into months. Our data quality is what makes the difference.
Modular & Scalable
Platform built once, applied repeatedly. Each new validated target adds a revenue stream without rebuilding the engine. Standardized campaigns make expansion seamless.
Conditional Activation
CA-NDCs combine 10× smaller size for deep tumor penetration with pH-dependent conditional activation, widening the therapeutic window so patients can be treated at doses that are safe and efficacious.
Pipeline
Building a scalable Pipeline
We are targeting clinically validated antigens in high-unmet-need solid tumors where conventional ADCs remain challenged by poor tumor penetration and systemic toxicity, with the goal of improving outcomes for patients with limited treatment options.
Team
Team
Nanolynx Biologics was founded in December 2025 and is led by a seasoned management team with a proven track record across biopharma R&D, AI-enabled biologics discovery, company building, and drug development.
Dr. Georg Rüedi
CEO and Co-founder
Georg is a seasoned biopharma R&D leader with 20+ years of multi‑modality experience, a track record of advancing more than ten drug candidates into the clinic, including two approved therapies, and a history of leading large cross‑functional teams of over 50 experts to deliver complex development programs.
Dr. Jean-Philippe Bürckert
CTO and Co-founder
Jean‑Philippe is a biotech innovator with 10+ years of drug‑discovery experience, specializing in nanobody and antibody machine‑learning–driven engineering, and a proven entrepreneurial track record, having secured $18M in seed financing for Ability in 2024.
Dr. Maurice Brozzo
CBO and Co-founder
Maurice is a biopharma executive with 15+ years spanning discovery and business development, deep expertise in biologics discovery, CMC, and CRO management, and a strong track record in sales strategy and building high‑value partnerships.
Investors
Investors
We are seeking long-term investors who share our vision of building a category-defining biologics company, grounded in scientific excellence, technological differentiation, and a capital-efficient development strategy.
Partners
Partners
We are open to partnerships with leading biopharma companies and academic groups who share our vision of next-generation, highly tumor-selective therapeutics.
Our partnering interests include targeted biologics, difficult-to-drug oncology targets, AI-enabled discovery approaches, and translational programs with the potential to create highly differentiated cancer medicines.
Contact us
Contact us
